Healthcare entity
FDA is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. Coverage clusters in market-trends, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each story carries 2 original sources on average, compared with 3.7 for the broader beat in this window.
Last mentioned: Aug 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
FDA is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. Coverage clusters in market-trends, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each story carries 2 original sources on average, compared with 3.7 for the broader beat in this window. Across a 132-day span, the pace is roughly 0.2 stories per week. Their average consequence score of 6.7 runs above the beat's 6.1 for that window. AMT-130 appears in 3 tracked Healthcare stories published from March 3, 2026 through July 12, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 643 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AMT-130. Shared-story counts are live from our verified record — not editorial picks.
Type B FDA Meeting Target
Planned follow-up to define Phase III and regulatory path for AMT-130.
AMT-260 Data Readout
Expected clinical data from Phase I/IIa epilepsy study in H1 2026.
Type A FDA Meeting
Discussed AMT-130 approval pathway; alignment not yet reached.
Fiscal Year End
Closed 2025 with $622.5 million in liquidity.
The FDA’s decision to accept existing AMT-130 clinical data for a BLA submission could fast-track the first disease-modifying treatment for Huntington’s disease, with major implications for healthcare systems, payers, and patients.
Source: insidermonkey.com · finance.yahoo.com
Clinical updates from uniQure, NTHI, and others signal tangible progress in gene therapy and oncology, offering potential new treatment options for patients with devastating diseases.
uniQure reported a strong cash position of $622.5 million, extending its operational runway into 2029. While the company continues to seek regulatory alignment with the FDA for its Huntington’s disease candidate AMT-130, it is advancing clinical trials for epilepsy and Fabry disease with key data readouts expected in 2026.
Source: Benzinga · Globenewswire_fr
AMT-130 is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
